.AN2 Therapeutics is rethinking its own service in reaction to poor midphase records, promising to lay off half its own workers and also stop a
Read moreALX’s fizzling CD47 response fee delivers inventory spiraling down
.ALX Oncology’s stage 2 gastric cancer cells response rate has deteriorated. After seeing its own CD47 blocker easily hammered management over the initial half of
Read moreAC Immune views ‘site’ potential in Alzheimer’s drug data
.After greater than two decades of service neurodegenerative health conditions, Swiss biotech hvac Immune cases it could have a game changer on its hands.The firm’s
Read more